HAOXI HEALTH TECHNOLOGY LTD
HAONASDAQTrading Snapshot
- Day Range
- $985.52 β $1,019.06
- 52-Week Range
- $2.61 β $4,352.00
- Volume
- $3.84B
- Avg Volume
- $2.68B
- Shares Outstanding
- 350,231
- Next Earnings
- Nov 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $33M
- Last Q Revenue
- $34M
- P/E Ratio
- -1.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-12.35
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β75.3%
Why Investors Own HAO
- βHigh-growth profile β revenue up +25.5% YoY with expanding US Equity exposure.
- βHealthy economics β 73% gross margin and 22% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
HAOXI HEALTH TECHNOLOGY LTD
HAOAbout HAOXI HEALTH TECHNOLOGY LTD
Haoxi Health Technology Limited, operating with its subsidiaries in China, specializes in providing digital marketing services. The company's offerings encompass online short video marketing, which it delivers to advertisers through its network of media partners, alongside custom-designed marketing strategies. These tailored solutions involve the careful planning, creation, distribution, and optimization of online advertisements across various digital platforms, all aimed at helping advertisers attract new customers, drive conversions, and cultivate consumer loyalty. Advertisements are strategically placed on leading online short video and social media platforms, including popular services like Toutiao, Douyin, WeChat, and Sina Weibo. Haoxi primarily serves an advertiser base within the healthcare industry. The company was founded in 2018 and is headquartered in Beijing, China.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
HAOXI HEALTH TECHNOLOGY LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift HAO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
HAOXI HEALTH TECHNOLOGY LTD announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.